Pancreatic Cancer Research

Journal articleGan To Kagaku Ryoho2016

[A Pancreatic Cancer Patient in Whom Pegfilgrastim Prophylaxis Did Not Prevent Severe Neutropenia Caused by the FOLFIRINOX Regimen].

Journal
Gan To Kagaku Ryoho
Published
1 July 2016
Citations
0
Type
Article

These are the paper’s bibliographic details. A summary of its population, design, endpoints and findings, each tied to a quote, has not been written for this paper yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

abstract license unknown

Recently, newer agents in regimens such as FOLFIRINOX have shown promising activity, being superior to gemcitabine as a single agent for unresectable pancreatic cancer patients with good performance status. Herein, we report a case of pancreatic cancer treated with the FOLFIRINOX regimen and pegfilgrastim prophylaxis as second-line treatment in a patient who failed this regimen. … Excerpt only: this text is the publisher’s. Read it in full at the source.